1,721,143 research outputs found
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet
Full text linkThe reliability of lung cancer screening based on low-dose computed tomography (LDCT) instead of X-ray is supported by a reduction of lung cancer mortality by 20% for high-risk subjects (1). As a consequence, this approach is recommended in heavy smokers.
However, some questions about the modality of screening have not been answered yet. Among these some issues appear more relevant:
What subjects should be considered at high risk?
How long time should elapse between screening rounds?
What patterns of nodules should be considered as suspicious for lung cancer?
What nodule size would induce a greater suspicion of malignancy
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable?
Full text linkRussell-Goldman et al1 recently published in CancerCytopathology an article on the cytologic-histologiccorrelation of programmed death-ligand 1 (PD-L1)in lung carcinomas
Tmb in nsclc: A broken dream?
Full text linkAlthough immune checkpoint inhibitors have changed the treatment paradigm of a variety of cancers, including non-small-cell lung cancer, not all patients respond to immunotherapy in the same way. Predictive biomarkers for patient selection are thus needed. Tumor mutation burden (TMB), defined as the total number of somatic/acquired mutations per coding area of a tumor genome (Mut/Mb), has emerged as a potential predictive biomarker of response to immune checkpoint inhibitors. We found that the limited use of TMB in clinical practice is due to the difficulty in its detection and compounded by several different biological, methodological and economic issues. The incorporation of both TMB and PD-L1 expression or other biomarkers into multivariable predictive models could result in greater predictive power
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?
No full text--
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?
No full textSince a chance for cure was found out in metastatic colorectal cancer (mCRC) patients undergoing a resection of liver and lung metastases, high tumor shrinkage by chemotherapy regimens and their combination with targeted agents have been addressed in potentially resectable mCRC. However, most mCRC patients cannot reach this opportunity because of tumor burden or metastatic sites. For these patients a salvage systemic therapy could be offered to prolong survival. To date, a huge number of clinical trials provided some evidences for the achievement of this goal. A lot of chemotherapeutic regimens in combination with biological therapies are now available. We tried to propose a simple way to choose the best options and to plan an optimal sequence of treatments. This tool could help the oncologists worldwide to better and easily manage mCRC patients who need salvage systemic therapy. © 2014 Informa UK, Ltd
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression
Full text link--
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?
No full textTumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients
- …
